| abstract |
The present invention provides novel methods and kits for determining whether a subject has or is susceptible to glaucoma. In one embodiment, the method comprises determining whether the method is a Frizzled-related protein (FRP), a wingless (Wnt) signaling pathway component, a gene activated by Wnt signaling, or a gene product of a gene activated by Wnt signaling. , Based on examining the relative level or activity of In some preferred embodiments, an assay is performed on trabecular meshwork cells obtained from a subject. The present invention provides glaucoma by contacting appropriate cells (eg, trabecular meshwork cells) with an effective amount of a compound that promotes the expression of trabecular meshwork genes involved in or regulated by Wnt signaling. It also relates to the method of treatment. |